Social Media Ideas for Astrazeneca

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted i...

<![CDATA[AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial ]]>

AstraZeneca in £20bn hit after heart disease drug hoped to be a potential blockbuster flops in trials

Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths related to heart disease.

AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

AstraZeneca’s Wainua fails main goal in late-stage heart disease trial

Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in an...

AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Oht...

AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney d...

AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug

AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FD...

AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor

AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor tipped to generate blockbuster sales. The comp...

HSBC downgrades AstraZeneca after key trial failure

AstraZeneca To Acquire Lung Cancer Drug License For $1.5B

Multinational pharma giant AstraZeneca said Tuesday that it has agreed to acquire worldwide rights to develop and commercialize a lung cancer drug for as much as $1.5 billion from...

AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified su...

AstraZeneca share price edges higher on Enhertu drug gains cancer treatment approval. What are analysts forecasting?

Mark Hartley takes a deep dive into the latest developments impacting the AstraZeneca share price, and sees how it weighs up against rivals. The post AstraZeneca share price edges...

AstraZeneca Expands Treatment Options for Breast Cancer Patients in Costa Rica The Costa Rica News

AstraZeneca Expands Treatment Options for Breast Cancer Patients in Costa Rica The Costa Rica News

FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and...

Texas Reaches $34M Settlement With AstraZeneca for Illegal Kickback Scheme

Texas Attorney General Ken Paxton secured a settlement with AstraZeneca Pharmaceuticals to resolve claims that the company engaged in an illegal kickback scheme that improperly inf...

India could be on the radar for AstraZeneca’s oral GLP-1 drug: MD

AstraZeneca’s MD hints at India’s potential inclusion in global trials for its promising oral GLP-1 weight loss and diabetes drug.

AstraZeneca, GSK intensify China ties with Sino Biopharm deals

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.

AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B

Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 inse...

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal stud...

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s t...

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio...